Survivin、BRCA1及class Ⅲ β-tubulin在非小细胞肺癌组织中的表达及与紫杉醇耐药的关系  

Expression of Survivin,BRCA1 and class Ⅲ β-tubulin in Non-small Cell Lung Cancer and Its Relationship with Resistance to Paclitaxel

作　　者：周正仕[1] 廖小方[1] 郑勤红[1] 何慧娟[1] 

机构地区：[1]衢州市人民医院,浙江衢州324000

出　　处：《肿瘤学杂志》2012年第11期806-810,共5页Journal of Chinese Oncology

摘　　要：[目的]探讨Survivin、BRCA1及class Ⅲβ-tubulin蛋白在非小细胞肺癌(NSCLC)中的表达及与紫杉醇耐药的关系。[方法]应用免疫组织化学法检测64例NSCLC患者Survivin、BRCA1及class Ⅲβ-tubulin蛋白的表达;给予紫杉醇为基础的化疗方案,分析上述蛋白表达与紫杉醇化疗敏感性的关系。[结果]Survivin阳性与class Ⅲβ-tubulin阳性患者对紫杉醇方案治疗的有效率(RR)分别低于Survivin阴性患者(27.8%vs71.4%,P<0.05)与class Ⅲβ-tubulin阴性患者(23.5%vs73.3%,P<0.01);而BRCA1阳性患者对紫杉醇方案治疗的RR高于BRCA1阴性患者(60.0%vs31.0%,P<0.05)。多因素分析表明classⅢβ-tubulin是NSCLC紫杉醇治疗无进展生存期(PFS)的独立影响因素(χ2=4.852,P=0.027),分期是与总生存期(OS)相关的独立影响因素(χ2=4.105,P=0.035)。[结论]NSCLC患者Survivin、class Ⅲβ-tubulin蛋白表达阳性及BRCA1蛋白表达阴性预示对紫杉醇治疗相对不敏感。[Purpose] To investigate the relationship between the expression of Survivin,BRCA1 and class Ⅲ β-tubulin proteins and resistance to paclitaxel in patients with non-small cell lung cancer（NSCLC）.[Methods] The expressions of Survivin,BRCA1 and class Ⅲ β-tubulin in 64 cases with NSCLC were detected by immunohistochemical method.Patients received paclitaxel-based chemotherapy.The relationship between the expression of 3 kinds of proteins and sensitivity of paclitaxel-chemothrapy was analyzed.[Results] The response rate（RR） of paclitaxel-based chemotherapy in patients with positive Survivin expression or positive class Ⅲ β-tubulin expression was lower than that in negative Survivin expression patients（27.8% vs 71.4%,P0.05） or negative class Ⅲ β-tubulin expression patients（23.5% vs 73.3%,P0.05）.RR in positive BRCA1 expression patients was higher than that in negative BRCA1 expression patients（60.0% vs 31.0%,P0.05）.Multivariate analysis showed that class Ⅲ β-tubulin was independent factor for progression-free survival（χ2=4.852,P=0.027） and stage was independent factor for overall survival（χ2=4.105,P=0.035）.[Conclusion] Positive expressions of Survivin and class Ⅲ β-tubulin and negative BRCA1 expression in NSCLC patients might be associated with resistance to paclitaxel-based chemotherapy.

关 键 词：SURVIVIN BRCA1 CLASS Ⅲ Β-TUBULIN 肺肿瘤 紫杉醇 耐药 

分 类 号：R734.2[医药卫生—肿瘤]